(2S)-2-amino-4-ethyl-2-methylhexanoic acid | 909024-69-7

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (2S)-2-amino-4-ethyl-2-methylhexanoic acid
• CAS: 909024-69-7
• 化学式: C₉H₁₉NO₂
• 分子量: 173.255
• InChiKey: WDAMHXABMOPUPC-VIFPVBQESA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.4
• 重原子数：
  12
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.89
• 拓扑面积：
  63.3
• 氢给体数：
  2
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  (2S)-2-amino-4-ethyl-2-methylhexanoic acid 在 甲醇 、 乙酰氯 作用下， 以52%的产率得到(2S)-2-amino-4-ethyl-2-methylhexanoic acid hydrochloride
  参考文献：
  名称：

  Amino acid derivatives

  摘要：

  本发明涉及一种利用公式中的化合物治疗疼痛的方法，其中R1、R2、R3和R4如本文所定义。该发明还涉及公式（I）的某些新颖衍生物。

  公开号：

  US20060247291A1
• 作为产物：
  描述：

  (3S,5S)-3-(2-ethylbutyl)-3-methyl-5-phenylmorpholin-2-one 在 20% Pd(OH)2 on carbon 盐酸 、 氢气 作用下， 以 乙醇 、 水 为溶剂， 20.0 ℃ 、414.01 kPa 条件下， 反应 24.0h， 生成 (2S)-2-amino-4-ethyl-2-methylhexanoic acid
  参考文献：
  名称：

  Amino acid derivatives

  摘要：

  本发明涉及一种利用公式中的化合物治疗疼痛的方法，其中R1、R2、R3和R4如本文所定义。该发明还涉及公式（I）的某些新颖衍生物。

  公开号：

  US20060247291A1

文献信息

• Substituted sulfonylaminoarylmethyl cyclopropanecarboxamide as VR1 receptor antagonists
  申请人：Hanazawa Takeshi

  公开号：US20060211741A1

  公开（公告）日：2006-09-21

  This invention provides a compound of the formula (I): wherein A and B are independently CR 12 or N; D and E are each independently CR 9 or N; R 1 represents (C 1 -C 6 )alkyl; R 2 represents hydrogen, halogen, hydroxy, (C 1 -C 6 )alkyl, halo(C 1 -C 6 )alkyl, hydroxy(C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy or (C 1 -C 6 )alkoxy-(C 1 -C 6 )alkyl; R 3 , R 4 , R 5 , R 6 , R 10 and R 11 each independently represent hydrogen, halogen, (C 1 -C 6 )alkyl, halo(C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy, hydroxy(C 1 -C 6 )alkyl or (C 1 -C 6 )alkoxy-(C 1 -C 6 )alkyl; or R 3 and R 4 are taken together with the carbon atom to which they are attached to form a 3- to 7-membered carbocyclic ring or heterocyclic ring in which one or two non-adjacent carbon atoms are optionally replaced by an oxygen atom, a sulfur atom or NH; R 7 and R 9 each independently represent hydrogen, halogen, (C 1 -C 6 )alkyl, halo(C 1 -C 6 )alkyl, hydroxy(C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy, hydroxy(C 1 -C 6 )alkoxy, (C 1 -C 6 )alkoxy-(C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy-(C 1 -C 6 )alkoxy, (C 1 -C 6 )alkylthio, (C 1 -C 6 )alkylsulfinyl, (C 1 -C 6 )alkylsulfonyl, NH 2 , [(C 1 -C 6 )alkyl]NH—, [(C 1 -C 6 )alkyl] 2 N—, H 2 N—(C 1 -C 6 )alkoxy, (C 1 -C 6 )alkyl-NH—(C 1 -C 6 )alkoxy, [(C 1 -C 6 )alkyl] 2 N(C 1 -C 6 )alkoxy; H 2 N—(C 1 -C 6 )alkoxy-(C 1 -C 6 )alkyl, (C 1 C 6 )alkyl-NH—(C 1 -C 6 )alkoxy-(C 1 -C 6 )alkyl, [(C 1 -C 6 )alkyl] 2 N(C 1 -C 6 )alkoxy-(C 1 -C 6 )alkyl or 5- or 6-membered heterocyclic ring containing at least one nitrogen atom; R 8 represents halogen, (C 1 -C 6 )alkyl, halo(C 1 -C 6 )alkyl, hydroxy(C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy, hydroxy(C 1 -C 6 )alkoxy, (C 1 -C 6 )alkoxy-(C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy-(C 1 -C 6 )alkoxy, halo(C 1 -C 6 )alkylsulfonyl, halo(C 1 -C 6 )alkylsulfinyl, halo(C 1 -C 6 )alkoxy, halo(C 1 -C 6 )alkylthio, [(C 1 -C 6 )alkyl]NH— or [(C 1 -C 6 )alkyl] 2 N—; or R 7 and R 8 , when E is CR 9 , are taken together with the carbon atoms to which they are attached form a 5-8 membered carbocyclic or heterocyclic ring, in which one or two non-adjacent carbon atoms are optionally replaced by oxygen, sulfur, N or NH groups, wherein the carbocyclic ring or the heterocyclic ring is unsubstituted or substituted with one or more substituents each independently selected from the group consisting of hydroxy, (C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy and hydroxy(C 1 -C 6 )alkyl; and R 12 represents hydrogen, halogen, (C 1 -C 6 )alkyl or hydroxy(C 1 -C 6 )alkyl; or a pharmaceutically acceptable salt or solvate thereof. These compounds are useful for the treatment of disease conditions caused by overactivation of VR1 receptor such of pain, or the like in mammalian. This invention also provides a pharmaceutical composition comprising the above compound.

  这项发明提供了一个化合物的结构式(I)：其中A和B分别独立地为CR12或N；D和E分别独立地为CR9或N；R1代表(C1-C6)烷基；R2代表氢、卤素、羟基、(C1-C6)烷基、卤代(C1-C6)烷基、羟基(C1-C6)烷基、(C1-C6)氧烷基或(C1-C6)氧烷基-(C1-C6)烷基；R3、R4、R5、R6、R10和R11分别独立地代表氢、卤素、(C1-C6)烷基、卤代(C1-C6)烷基、(C1-C6)氧烷基、羟基(C1-C6)烷基或(C1-C6)氧烷基-(C1-C6)烷基；或者R3和R4一起与它们连接的碳原子形成一个3-至7-成员的碳环或杂环，其中一个或两个非相邻的碳原子可以选择性地被氧原子、硫原子或NH取代；R7和R9分别独立地代表氢、卤素、(C1-C6)烷基、卤代(C1-C6)烷基、羟基(C1-C6)烷基、(C1-C6)氧烷基、羟基(C1-C6)氧烷基、(C1-C6)氧烷基-(C1-C6)烷基、(C1-C6)氧烷基-(C1-C6)氧烷基、(C1-C6)烷基硫、(C1-C6)烷基亚硫基、(C1-C6)烷基磺基、NH2、[(C1-C6)烷基]NH—、[(C1-C6)烷基]2N—、H2N—(C1-C6)氧烷基、(C1-C6)烷基-NH—(C1-C6)氧烷基、[(C1-C6)烷基]2N(C1-C6)氧烷基；H2N—(C1-C6)氧烷基-(C1-C6)烷基、(C1C6)烷基-NH—(C1-C6)氧烷基-(C1-C6)烷基、[(C1-C6)烷基]2N(C1-C6)氧烷基-(C1-C6)烷基或含有至少一个氮原子的5-或6-成员杂环，R8代表卤素、(C1-C6)烷基、卤代(C1-C6)烷基、羟基(C1-C6)烷基、(C1-C6)氧烷基、羟基(C1-C6)氧烷基、(C1-C6)氧烷基-(C1-C6)烷基、(C1-C6)氧烷基-(C1-C6)氧烷基、卤代(C1-C6)烷基磺基、卤代(C1-C6)烷基亚硫基、卤代(C1-C6)烷基氧基、卤代(C1-C6)烷基硫基、[(C1-C6)烷基]NH—或[(C1-C6)烷基]2N—；或者当E为CR9时，R7和R8一起与它们连接的碳原子形成一个5-8成员的碳环或杂环，其中一个或两个非相邻的碳原子可以选择性地被氧、硫、N或NH基团取代，其中碳环或杂环未取代或取代有一个或多个取代基，每个取代基独立地选自羟基、(C1-C6)烷基、(C1-C6)氧烷基和羟基(C1-C6)烷基；R12代表氢、卤素、(C1-C6)烷基或羟基(C1-C6)烷基；或其药学上可接受的盐或溶剂。这些化合物对于治疗由VR1受体过度激活引起的疾病状况，如哺乳动物中的疼痛等，是有用的。这项发明还提供了包含上述化合物的药物组合物。
• Substituted Aryloxymethyl Bicyclicmethyl Acetamide Compounds
  申请人：Inoue Tadashi

  公开号：US20060270682A1

  公开（公告）日：2006-11-30

  This invention provides a compound of the formula (I): wherein A=B=D represents NR 10 —C(O)—NR 9 , S—C(O)—NR 9 , NR 9 —C(O)—S, NR 9 —C(O)—O, CR 10 —C(O)—NR 9 , O—C(O)—NR 9 , NR 10 —C(O)—CR 9 , NR 10 —NR 9 —C(O), C(O)—NR 9 —NR 10 , NR 10 —N═CR 9 , N═N—CR 9 , NR 10 —CR 9 ═N, N═CR 9 —NR 10 , NR 10 —N═N, N═N—NR 10 , S—CR 9 ═N or N═CR 9 —S; X 1 represents CR 1 or N; X 2 and X 3 each independently represents CR 8 or N; R 1 , R 6 , R 8 , R 9 and R 10 each independently represents hydrogen, halogen, hydroxy, (C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy, hydroxy(C 1 -C 6 )alkoxy, (C 1 -C 6 )alkoxy-(C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy-(C 1 -C 6 )alkoxy, halo(C 1 -C 6 )alkyl, (C 1 -C 6 )alkylthio, (C 1 -C 6 )alkylsulfinyl or (C 1 -C 6 )alkylsulfonyl; R 2 , R 3 , R 4 , and R 5 each independently represents hydrogen, (C 1 -C 6 )alkyl, halogen, halo(C 1 -C 6 )alkyl, or hydroxy(C 1 -C 6 )alkyl; and R 7 represents halogen, (C 1 -C 6 )alkyl, halo(C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy, hydroxy(C 1 -C 6 )alkoxy, (C 1 -C 6 )alkoxy-(C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy-(C 1 -C 6 )alkoxy, [(C 1 -C 6 )alkyl]NH— or [(C 1 -C 6 )alkyl] 2 N—; or a pharmaceutically acceptable salt thereof, provided that: (i) when A=B=D represents NR 10 —N═N or N═N—NR 10 , then R 2 represents (C 1 -C 6 )alkyl, halogen, halo(C 1 -C 6 )alkyl or hydroxy(C 1 -C 6 )alkyl; or (ii) when A=B=D represents NR 10 —N═N or N═N—NR 10 , and R 2 represents (C 1 -C 6 )alkyl, then R 7 represents halogen, (C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy, hydroxy(C 1 -C 6 )alkoxy, (C 1 -C 6 )alkoxy-(C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy-(C 1 -C 6 )alkoxy, [(C 1 -C 6 )alkyl]NH— or [(C 1 -C 6 )alkyl] 2 N—. These compounds are useful for the treatment of disease conditions caused by overactivation of VR1 receptor such of pain, or the like in mammalian. This invention also provides a pharmaceutical composition comprising the above compound.

  本发明提供了式（I）的化合物：其中A = B = D表示NR10-C（O）-NR9，S-C（O）-NR9，NR9-C（O）-S，NR9-C（O）-O，CR10-C（O）-NR9，O-C（O）-NR9，NR10-C（O）-CR9，NR10-NR9-C（O），C（O）-NR9-NR10，NR10-N═CR9，N═N-CR9，NR10-CR9═N，N═CR9-NR10，NR10-N═N，N═N-NR10，S-CR9═N或N═CR9-S; X1表示CR1或N; X2和X3分别独立地表示CR8或N; R1，R6，R8，R9和R10分别独立地表示氢，卤素，羟基，（C1-C6）烷基，（C1-C6）烷氧基，羟基（C1-C6）烷氧基，（C1-C6）烷氧基-（C1-C6）烷基，（C1-C6）烷氧基-（C1-C6）烷氧基，卤代（C1-C6）烷基，（C1-C6）烷基硫醇，（C1-C6）烷基亚砜基或（C1-C6）烷基磺酰基; R2，R3，R4和R5分别表示氢，（C1-C6）烷基，卤素，卤代（C1-C6）烷基或羟基（C1-C6）烷基; R7表示卤素，（C1-C6）烷基，卤代（C1-C6）烷基，（C1-C6）烷氧基，羟基（C1-C6）烷氧基，（C1-C6）烷氧基-（C1-C6）烷基，（C1-C6）烷氧基-（C1-C6）烷氧基，[(C1-C6)烷基]NH-或[(C1-C6)烷基]2N-;或其药学上可接受的盐，前提是：（i）当A = B = D表示NR10-N═N或N═N-NR10时，R2表示（C1-C6）烷基，卤素，卤代（C1-C6）烷基或羟基（C1-C6）烷基;或（ii）当A = B = D表示NR10-N═N或N═N-NR10，并且R2表示（C1-C6）烷基时，R7表示卤素，（C1-C6）烷基，（C1-C6）烷氧基，羟基（C1-C6）烷氧基，（C1-C6）烷氧基-（C1-C6）烷基，（C1-C6）烷氧基-（C1-C6）烷氧基，[(C1-C6)烷基]NH-或[(C1-C6)烷基]2N-。这些化合物对于治疗哺乳动物中由VR1受体过度激活引起的疾病状况，例如疼痛等，具有用途。本发明还提供了包含上述化合物的制药组合物。
• SUBSTITUTED PHENYLMETHYL BICYCLOCARBOXYAMIDE COMPOUNDS
  申请人：Ando Koji

  公开号：US20100087480A1

  公开（公告）日：2010-04-08

  This invention provides a compound of the formula (I). These compounds are useful for the treatment of disease conditions caused by overactivation of the VR1 receptor such as pain, or the like in mammal. This invention also provides a pharmaceutical composition comprising the above compound.

  这项发明提供了一种化合物，其化学式为（I）。这些化合物对于治疗由VR1受体过度激活引起的疾病症状，如哺乳动物中的疼痛等，具有益处。该发明还提供了一种包含上述化合物的药物组合物。
• SUBSTITUTED PYRIDYLMETHYL BICYCLICCARBOXYAMIDE COMPOUNDS
  申请人：Nagayama Satoshi

  公开号：US20090318497A1

  公开（公告）日：2009-12-24

  This invention provides a compound of the formula (I): wherein A 1 is N and A 2 is CR 7 , or A 1 is CR 7 and A 2 is N; Y 1 , Y 2 and Y 3 are each independently CH or N, Y 4 and Y 5 are each independently CR 8 or N, with the proviso that when one of Y 1 , Y 2 , Y 3 , Y 4 and Y 5 is N, the others are not N; R 1 and R 2 are each independently hydrogen, halogen, (C 1 -C 6 )alkyl, halo(C 1 -C 6 )alkyl or hydroxy(C 1 -C 6 )alkyl; R 3 and R 8 are each independently hydrogen, halogen, hydroxy, (C 1 -C 6 )alkyl, hydroxy(C 1 -C 6 )alkoxy, (C 1 -C 6 )alkoxy-(C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy-(C 1 -C 6 )alkoxy, halo(C 1 -C 6 )alkyl, (C 1 -C 6 )alkylthio, (C 1 -C 6 )alkylsulfinyl or (C 1 -C 6 )alkylsulfonyl; R 4 is halogen, (C 1 -C 6 )alkyl, (C 3 -C 6 )cycloalkyl, halo(C 1 -C 6 )alkyl, hydroxy(C 1 -C 6 )alkyl, halo(C 1 -C 6 )alkoxy, hydroxy(C 1 -C 6 )alkoxy, (C 1 -C 6 )alkoxy-(C 1 -C 6 )alkyl, (C 1 -C 6 )alkoxy-(C 1 -C 6 )alkoxy, halo(C 1 -C 6 )alkylsulfonyl, halo(C 1 -C 6 )alkylsulfinyl, halo(C 1 -C 6 )alkylthio, [(C 1 -C 6 )alkyl]NH— or [(C 1 -C 6 )alkyl] 2 N—; and R 5 , R 6 and R 7 are each independently hydrogen, halogen, (C 1 -C 6 )alkyl, hydroxy(C 1 -C 6 )alkyl, or (C 1 -C 6 )alkoxy; or a pharmaceutically acceptable salt, solvate thereof. These compounds are useful for the treatment of disease conditions caused by overactivation of the VR1 receptor such as pain, or the like in mammal. This invention also provides a pharmaceutical composition comprising the above compound.

  本发明提供了一种式（I）的化合物：其中A1为N且A2为CR7，或者A1为CR7且A2为N；Y1、Y2和Y3分别独立地为CH或N，Y4和Y5分别独立地为CR8或N，但是当Y1、Y2、Y3、Y4和Y5中的一个为N时，其他的不为N；R1和R2各自独立地为氢、卤素、（C1-C6）烷基、卤代（C1-C6）烷基或羟基（C1-C6）烷基；R3和R8各自独立地为氢、卤素、羟基、（C1-C6）烷基、羟基（C1-C6）氧烷基、（C1-C6）氧烷基-(C1-C6)烷基、（C1-C6）氧烷基-(C1-C6)氧烷基、卤代（C1-C6）烷基、（C1-C6）烷基硫醇基、（C1-C6）烷基亚砜基或（C1-C6）烷基磺酰基；R4为卤素、（C1-C6）烷基、（C3-C6）环烷基、卤代（C1-C6）烷基、羟基（C1-C6）烷基、卤代（C1-C6）氧烷基、羟基（C1-C6）氧烷基、（C1-C6）氧烷基-(C1-C6)烷基、（C1-C6）氧烷基-(C1-C6）氧烷基、卤代（C1-C6）烷基磺酰基、卤代（C1-C6）烷基亚砜基、卤代（C1-C6）烷基硫醇基、[(C1-C6)烷基]NH-或[(C1-C6)烷基]2N-；以及R5、R6和R7各自独立地为氢、卤素、（C1-C6）烷基、羟基（C1-C6）烷基或（C1-C6）氧烷基；或其药学上可接受的盐、溶剂。这些化合物对于治疗由VR1受体过度激活引起的疾病状况，例如哺乳动物中的疼痛等，是有用的。本发明还提供了包含上述化合物的制药组合物。
• SUBSTITUTED N-BICYCLICALKYL BICYCLICCARBOXYAMIDE COMPOUNDS
  申请人：Kawashima Tadashi

  公开号：US20090253740A1

  公开（公告）日：2009-10-08

  This invention provides a compound of the formula (I): And their use for the treatment of disease conditions caused by overactivation of the VR1 receptor such as pain, or the like in mammal. This invention also provides a pharmaceutical composition comprising the above compound.

  本发明提供了一个公式(I)的化合物，以及它们用于治疗由VR1受体过度激活引起的疾病状态，如哺乳动物中的疼痛等。本发明还提供了包含上述化合物的药物组合物。